Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 1,646,299 shares, a growth of 96.5% from the July 30th total of 837,868 shares. Currently, 7.6% of the company’s stock are short sold. Based on an average daily trading volume, of 33,615,368 shares, the short-interest ratio is currently 0.0 days.
Valion Bio, Inc. Common Stock Trading Up 18.1%
Shares of Valion Bio, Inc. Common Stock stock opened at $3.57 on Tuesday. The company has a fifty day simple moving average of $0.41 and a 200-day simple moving average of $0.72. Valion Bio, Inc. Common Stock has a 12-month low of $2.79 and a 12-month high of $80.19. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.74. The stock has a market cap of $79.22 million, a price-to-earnings ratio of -0.56 and a beta of 1.85.
Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.17) EPS for the quarter, topping the consensus estimate of ($408.00) by $405.83.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on VBIO
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Valion Bio, Inc. Common Stock stock. Foster & Motley Inc. acquired a new stake in Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 53,728 shares of the company’s stock, valued at approximately $2,715,000. Foster & Motley Inc. owned about 1.29% of Valion Bio, Inc. Common Stock at the end of the most recent quarter. 4.25% of the stock is owned by institutional investors.
About Valion Bio, Inc. Common Stock
Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.
The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.
Featured Stories
- Five stocks we like better than Valion Bio, Inc. Common Stock
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
